Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Exact Sciences Corporation (EXAS : NSDQ)

• Company Description    Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer. The company has developed an accurate, non-invasive, patient-friendly screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. The company is currently working on the development of additional tests for other types of cancer, with the goal of becoming a leader in cancer screening and diagnostics. Exact Sciences currently has two of the brands in cancer diagnostics, Cologuard and Oncotype DX. Cologuard Test: This is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Oncotype DX: Genomic Health's first product, the 21-gene Oncotype DX breast cancer test is used to predict the likelihood of cancer recurrence, patient survival within 10 years of diagnosis and chemotherapy benefit for early-stage patients. Number of Employees: 6,500

• Price / Volume Information    Yesterday's Closing Price: $50.55 Daily Weekly Monthly 20 Day Moving Average: 2,657,519 shares Shares Outstanding: 175.95 (millions) Market Capitalization: $8,894.02 (millions) Beta: 1.23 52 Week High: $133.99 52 Week Low: $46.15 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -25.49% -18.35% 12 Week -31.81% -26.01% Year To Date -35.05% -22.76%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 5505 ENDEAVOR LANE - MADISON,WI 53719 USA ph: 608-535-8815 fax: 608-284-5701 meganjones@exactsciences.com http://www.exactsciences.com

• General Corporate Information    Officers Kevin T. Conroy - President; Chief Executive Officer and Chairman Jeffrey T. Elliott - Executive Vice President; Chief Financial Officer; Paul Clancy - Director Freda Lewis-Hall - Director Pierre Jacquet - Director Peer Information Exact Sciences Corporation (CORR.) Exact Sciences Corporation (RSPI) Exact Sciences Corporation (CGXP) Exact Sciences Corporation (BGEN) Exact Sciences Corporation (GTBP) Exact Sciences Corporation (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 30063P105 SIC: 8071 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 07/27/22 Share - Related Items Shares Outstanding: 175.95 Most Recent Split Date: (:1) Beta: 1.23 Market Capitalization: $8,894.02 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.08 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.26 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 07/27/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.73 Price/Cash Flow: - Price / Sales: 4.80 EPS Growth vs. Year Ago Period: -477.78% vs. Previous Quarter: 18.75% Sales Growth vs. Year Ago Period: 21.01% vs. Previous Quarter: 2.69% ROE 03/31/22 - -21.82 12/31/21 - -16.95 09/30/21 - -12.06 ROA 03/31/22 - -11.23 12/31/21 - -8.89 09/30/21 - -6.21 Current Ratio 03/31/22 - 2.53 12/31/21 - 2.76 09/30/21 - 2.27 Quick Ratio 03/31/22 - 2.29 12/31/21 - 2.56 09/30/21 - 2.14 Operating Margin 03/31/22 - -40.26 12/31/21 - -33.71 09/30/21 - -22.10 Net Margin 03/31/22 - -40.26 12/31/21 - -33.71 09/30/21 - -46.14 Pre-Tax Margin 03/31/22 - -40.59 12/31/21 - -47.68 09/30/21 - -58.88 Book Value 03/31/22 - 18.52 12/31/21 - 19.66 09/30/21 - 20.11 Inventory Turnover 03/31/22 - 4.80 12/31/21 - 4.84 09/30/21 - 4.80 Debt-to-Equity 03/31/22 - 0.67 12/31/21 - 0.64 09/30/21 - 0.55 Debt-to-Capital 03/31/22 - 40.10 12/31/21 - 39.16 09/30/21 - 35.31

Powered by Zacks Investment Research ©